3.
Baseline characteristics after propensity score-matched stratification by maintenance treatment
| Characteristics | Bev+Pem (n=54) [n (%)] | Pem (n=58) [n (%)] | None (n=98) [n (%)] | P |
| ECOG PS, Eastern Cooperative Oncology Group Performance Score; EGFR, epidermal growth factor receptor; Bev, bevacizumab; Pem, pemetrexed. | ||||
Age (
) (year)
|
55.5±10.5 | 55.3±9.9 | 56.7±10.5 | 0.989 |
| ≥60 years | 21 (38.9) | 19 (32.8) | 42 (42.9) | 0.458 |
| Male | 24 (44.4) | 29 (50.0) | 48 (49.0) | 0.817 |
| ECOG PS | 0.086 | |||
| 0−1 | 53 (98.1) | 56 (96.6) | 86 (87.8) | |
| ≥2 | 1 (1.9) | 3 (5.2) | 12 (12.2) | |
| Smoking history | 14 (25.9) | 20 (34.5) | 33 (33.7) | 0.454 |
| Comorbidities | 28 (51.9) | 29 (50.0) | 48 (49.0) | 0.944 |
| Adenocarcinoma | 53 (98.1) | 58 (100) | 98 (100) | 0.982 |
| EGFR positive | 12 (22.2) | 9 (15.5) | 32 (32.7) | 0.292 |
| ALK positive | 7 (13.0) | 1 (1.7) | 9 (9.2) | 0.080 |
| Brain metastases | 10 (18.5) | 5 (8.6) | 12 (12.2) | 0.286 |
| Pleural invasion | 25 (46.3) | 24 (41.4) | 36 (36.7) | 0.510 |
| Weight loss >5% | 3 (5.6) | 1 (1.7) | 9 (9.2) | 0.170 |
| History of hemoptysis | 4 (7.4) | 2 (3.4) | 9 (9.2) | 0.404 |
| Previous surgery | 11 (20.4) | 12 (20.7) | 15 (15.3) | 0.617 |
| Radiotherapy history | 13 (24.1) | 7 (12.1) | 20 (20.4) | 0.242 |